In addition to the work the AMA is doing on the Recovery Plan, we are also advocating at the federal and state levels on key issues in public health and pandemic response.

Subscribe to AMA Advocacy Update

Stay current on the latest on the issues impacting physicians, patients and the health care environment with the AMA’s Advocacy Update Newsletter. 

  • Highlighting physician advocacy efforts to help their patients with a substance use disorder or chronic pain.
  • The then AMA Chair Bobby Mukkamala, MD, participated in a public workshop on naloxone access sponsored by the Regan-Udall Foundation for the Food and Drug Administration. AMA called on all naloxone manufacturers to make their life-saving products more accessible, including over-the-counter; further urged the Administration and Congress to remove the prescription status of naloxone to increase access to the life-saving opioid-related overdose reversal agent.
  • Provided comments (PDF) on the CDC’s proposed updated guideline for prescribing opioids. CDC’s proposed comments include nearly all previous AMA recommendations, including removing harmful thresholds on dose and quantity that have harmed tens of thousands of patients.
  • Supported the Biden Administration’s National Drug Control Strategy in its focus on harm reduction, encouraging the Administration to continue to help remove barriers to medications for opioid use disorder as well as harm reduction services.
  • Urged (PDF) congressional leaders to take steps to address nearly 15 years of repeated failures by health insurance companies to comply with the landmark mental health and substance use disorder parity law. Continuing efforts with National Association of Insurance Commissioners and National Association of Attorneys General to support greater state-level enforcement of parity laws.
  • Asked (PDF) the Biden Administration to take additional steps to remove the prescription status of naloxone and make it more available over the counter.
  • Developed a toolkit (PDF) in collaboration with Manatt Health highlighting effective policies for states to combat drug overdoses.
  • Supported multiple pieces of legislation at the state level:
    • Maryland S.B. 419 and H.B. 1086 (PDF) would ensure that opioid litigation settlement funds from major distributors would go to public health and treatment.
    • Companion bills in the Minnesota House and Senate (PDF) will help physicians who treat patients with intractable pain, including opioid therapy, practice without fear of an investigation, disenrollment or termination for providing care that may exceed recommended prescribing limits in state or federal guidelines.
    • New Mexico H.B. 52 authorizes the use of fentanyl test strips and other drug checking supplies.
    • Wisconsin S.B. 600, which was signed into law in March, removes fentanyl test strips from the state’s drug paraphernalia law.
  • Held a national webinar with physician experts on the stigma facing patients with pain and physician fears when prescribing opioids.
  • The Johns Hopkins School of Public Health released the “Primer of Spending Funds from the Opioid Litigation: A Guide for State and Local Decision Makers,” (PDF) part of the Principles for the Use of Funds From the Opioid Litigation (PDF) supported by the AMA.
  • The House Energy and Commerce Committee unanimously reported out the “Restoring Hope for Mental Health and Well-Being Act of 2022,” which would reauthorize key programs within the Substance Abuse and Mental Health Services Administration.
  • Requested (PDF) funding of $35 million for the CDC and $25 million for the NIH for FY 2023 to conduct public health research into firearm morbidity and mortality prevention.
  • Released a statement (PDF) on the Texas school shooting calling on lawmakers, leaders and advocates to take action against firearm violence.
  • Published a statement (PDF) reiterating the need for gun violence prevention measures after the Tulsa shooting.
  • Sent a comment letter (PDF) to the U.S. House of Representatives in support of the “Protecting Our Kids Act.”
  • Continuing to work at the federal and state levels to advocate for a comprehensive response to the public health emergency (PHE)—including telehealth expansion, financial relief, testing, vaccination and more (Visit COVID-19 Advocacy efforts for more details—highlights are included below).
  • The Health Resources and Services Administration (HRSA) announced $9 billion in Phase 4 Provider Relief Fund payments following AMA advocacy.
  • HHS disbursed an additional $2 billion in Provider Relief Fund Phase 4 payments.
  • Nearly $11.5 billion in Provider Relief Fund Phase 4 payments has now been distributed to more than 78,000 providers in all 50 states, Washington, D.C., and five territories. This is in addition to HRSA’s distribution of American Rescue Plan rural payments totaling nearly $7.5 billion in funding to more than 44,000 providers since Nov. 2021.
  • Successfully urged HRSA to extend the reporting period for recipients of Period 1 and Period 2 Provider Relief Funds.
  • Secured a one-year delay to the start of repayment, a reduction in the per-claim repayment amount and a reduction in the interest on any outstanding funds from 10.25% to 4%.
  • Urged (PDF) the Surgeon General to take action against COVID-19 misinformation.
  • Food and Drug Administration proposed a ban on menthol-flavored cigarettes.

Learn more about our efforts issues covered in the AMA Recovery Plan for America’s Physicianspopulation care and health disparities and removing obstacles to care.

Featured Stories